Commercial RT-PCR Tests Compared to Culture for Bacterial Gastroenteritis
By LabMedica International staff writers Posted on 11 Jan 2022 |
Image: ProGastro SSCS is a multiplex real time PCR for the detection and differentiation of Salmonella, Shigella, Campylobacter, (C. jejuni and C. coli only, undifferentiated) nucleic acids and Shiga Toxin 1 (stx1) and Shiga Toxin 2 (stx2) genes (Photo courtesy of Hologic)
Nucleic acid-based testing (culture-independent diagnostic testing, CIDT) for bacterial gastroenteritis offers three major advantages over culture-based diagnosis: it has better analytical sensitivity, is less labor intensive through automation, and has faster turnaround times.
Multiple commercial nucleic acid test assays (i.e. real-time PCR, RT-PCR) are available, testing at a minimum of four pathogens (Salmonella, Campylobacter, Shiga toxin-producing Escherichia coli (STEC), and Shigella). However, there are many caveats associated with CIDT for bacterial gastroenteritis, and gaps in the evaluation of commercial assays.
Clinical Microbiologists at the University of Calgary (Calgary, AB, Canada) and their colleagues used clinical stool specimens and contrived samples comprising commonly circulating species, serotypes, biovars, and/or toxin subtypes were for a comparison of four commercial RT-PCR tests. The four tests were: RIDAGENE Bacterial Stool Panel and EHEC/EPEC Panel (R-Biopharm AG, Darmstadt, Germany); FTD Bacterial Gastroenteritis assay (Fast Track Diagnostics, Luxembourg); BD MAX Enteric Bacterial Panel and Extended Enteric Bacterial Panel (BD Canada, Mississauga, ON, Canada); Prodesse ProGastr SSCS Assay (Hologic Inc., San Diego, CA, USA).
The four commercial RT-PCR assays were challenged with 67 contrived stool specimens, each spiked with an isolate representing different Campylobacter species, Salmonella serotypes, Shigella species and serotypes, STEC toxin subtypes, Y. enterocolitica serotypes/biotypes, and Yersina spp; these isolates are the common circulating types in Alberta, Canada. All assays gave positive results for C. jejuni, C. coli, Y. enterocolitica, and all species and serotypes of Shigella, but negative results for Y. non-enterocoltica spp. and C. upsaliensis. Most Shiga toxin subtypes were detected by all assays except for stx2f, which was detected by Ridagene.
The performance of the four commercial assays was assessed using 171 clinical fecal specimens collected prospectively, which were initially tested by culture at the frontline diagnostic laboratories. This included feces that were 125 culture-positive or 46 culture-negative for Campylobacter, Salmonella, Shigella, STEC, or Y. enterocolitica. Using culture as a reference standard, the sensitivity for all organisms (excluding Yersinia) was >96% for all four assays and specificity was >90%, except for BD Max (87%).
The authors concluded that their study provided a third-party evaluation of four commercially available RT-PCR assays for bacterial gastroenteritis and demonstrated the assays to be mostly equivalent to each other and culture with a few caveats. Depending on the prevalence of certain stx sub-types, Yersinia species, and Campylobacter species in a laboratory's jurisdiction, without further improvement in culture-independent tests, culture methods remain critical for the detection of these pathogens. The study was published on January 1, 2022 in the International Journal of Infectious Diseases.
Related Links:
University of Calgary
R-Biopharm
Fast Track Diagnostics
BD Canada
Hologic
Multiple commercial nucleic acid test assays (i.e. real-time PCR, RT-PCR) are available, testing at a minimum of four pathogens (Salmonella, Campylobacter, Shiga toxin-producing Escherichia coli (STEC), and Shigella). However, there are many caveats associated with CIDT for bacterial gastroenteritis, and gaps in the evaluation of commercial assays.
Clinical Microbiologists at the University of Calgary (Calgary, AB, Canada) and their colleagues used clinical stool specimens and contrived samples comprising commonly circulating species, serotypes, biovars, and/or toxin subtypes were for a comparison of four commercial RT-PCR tests. The four tests were: RIDAGENE Bacterial Stool Panel and EHEC/EPEC Panel (R-Biopharm AG, Darmstadt, Germany); FTD Bacterial Gastroenteritis assay (Fast Track Diagnostics, Luxembourg); BD MAX Enteric Bacterial Panel and Extended Enteric Bacterial Panel (BD Canada, Mississauga, ON, Canada); Prodesse ProGastr SSCS Assay (Hologic Inc., San Diego, CA, USA).
The four commercial RT-PCR assays were challenged with 67 contrived stool specimens, each spiked with an isolate representing different Campylobacter species, Salmonella serotypes, Shigella species and serotypes, STEC toxin subtypes, Y. enterocolitica serotypes/biotypes, and Yersina spp; these isolates are the common circulating types in Alberta, Canada. All assays gave positive results for C. jejuni, C. coli, Y. enterocolitica, and all species and serotypes of Shigella, but negative results for Y. non-enterocoltica spp. and C. upsaliensis. Most Shiga toxin subtypes were detected by all assays except for stx2f, which was detected by Ridagene.
The performance of the four commercial assays was assessed using 171 clinical fecal specimens collected prospectively, which were initially tested by culture at the frontline diagnostic laboratories. This included feces that were 125 culture-positive or 46 culture-negative for Campylobacter, Salmonella, Shigella, STEC, or Y. enterocolitica. Using culture as a reference standard, the sensitivity for all organisms (excluding Yersinia) was >96% for all four assays and specificity was >90%, except for BD Max (87%).
The authors concluded that their study provided a third-party evaluation of four commercially available RT-PCR assays for bacterial gastroenteritis and demonstrated the assays to be mostly equivalent to each other and culture with a few caveats. Depending on the prevalence of certain stx sub-types, Yersinia species, and Campylobacter species in a laboratory's jurisdiction, without further improvement in culture-independent tests, culture methods remain critical for the detection of these pathogens. The study was published on January 1, 2022 in the International Journal of Infectious Diseases.
Related Links:
University of Calgary
R-Biopharm
Fast Track Diagnostics
BD Canada
Hologic
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia